Clinical studies reveal that both CD68+ M1 and CD163+ M2 TAMs correlate with lymph node metastasis, with CD163+ TAMs further predicting advanced FIGO stage and poor prognosis (22). Here, CD163 is linked to metastatic malignant neoplasm in the lymph nodes.